{
    "clinical_study": {
        "@rank": "80816", 
        "brief_summary": {
            "textblock": "To compare the safety and efficacy of antiretroviral therapy (zidovudine plus either\n      didanosine or dideoxycytidine) versus antiretroviral therapy plus intravenous cytarabine\n      (Ara-C) versus antiretroviral therapy plus intrathecal Ara-C in the maintenance or\n      improvement of neurological function over 6 months in HIV-infected individuals who have\n      developed progressive multifocal leukoencephalopathy (PML). To compare the effect of these\n      three treatment regimens on Karnofsky score and MRI studies.\n\n      The effectiveness of Ara-C in the treatment of PML, caused by a human DNA papovavirus\n      (designated JC virus) infection, has not been determined, although the most encouraging\n      results have occurred with intrathecal administration of the drug."
        }, 
        "brief_title": "Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients", 
        "completion_date": {
            "#text": "April 1997", 
            "@type": "Actual"
        }, 
        "condition": [
            "HIV Infections", 
            "Leukoencephalopathy, Progressive Multifocal"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Leukoencephalopathy, Progressive Multifocal", 
                "Leukoencephalopathies"
            ]
        }, 
        "detailed_description": {
            "textblock": "The effectiveness of Ara-C in the treatment of PML, caused by a human DNA papovavirus\n      (designated JC virus) infection, has not been determined, although the most encouraging\n      results have occurred with intrathecal administration of the drug.\n\n      Patients are randomized to receive antiretroviral therapy alone (AZT plus ddI or ddC),\n      antiretroviral therapy plus intravenous Ara-C, or antiretroviral therapy plus intrathecal\n      Ara-C. All patients receive 24 weeks of antiretroviral therapy. Beginning at week 2,\n      patients on the intravenous Ara-C arm receive daily infusions of Ara-C over 5 days, with\n      cycles repeating every 21 days. Patients on the intrathecal Ara-C arm receive single\n      administrations of Ara-C at weeks 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, and 24. A brain biopsy\n      confirmation or in situ hybridization will be required within 7 days after study entry.\n      Patients are followed every 4 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Local intralesional chemotherapy for mucocutaneous Kaposi's sarcoma.\n\n          -  Topical antifungals, clotrimazole, ketoconazole, fluconazole, and amphotericin B for\n             treatment of mucosal and esophageal candidiasis.\n\n          -  Foscarnet for newly developed CMV infection, only after discussion with the protocol\n             chair.\n\n          -  Prophylactic and maintenance therapy for other opportunistic infections, provided\n             patients are considered clinically stable.\n\n          -  No more than 1000 mg/day acyclovir for herpes simplex.\n\n          -  Antibiotics for bacterial infections as clinically indicated.\n\n          -  Antipyretics, analgesics, and antiemetics.\n\n        Concurrent Treatment:\n\n        Allowed:\n\n          -  Local radiation therapy for mucocutaneous Kaposi's sarcoma.\n\n        Patients must have:\n\n          -  HIV infection.\n\n          -  Confirmed PML.\n\n          -  No other current active opportunistic infections requiring systemic therapy.\n\n          -  Life expectancy of at least 3 months.\n\n        NOTE:\n\n          -  A durable power of attorney is recommended where severe neurologic or psychiatric\n             impairment can be foreseen while the patient is on study.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Current active cryptococcal meningitis, cytomegaloviral encephalitis, toxoplasmosis\n             encephalitis, CNS lymphoma, or neurosyphilis.\n\n        NOTE:\n\n          -  Patients on maintenance therapy for cryptococcal meningitis or toxoplasmosis\n             encephalitis that has been stable for 4 months are permitted.\n\n          -  Conditions that seriously increase risk of a surgical procedure (e.g., coagulopathy,\n             severe thrombocytopenia).\n\n          -  Any other disease that would interfere with evaluation of the patient.\n\n          -  Other life-threatening complications likely to cause death in < 3 months.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Ganciclovir.\n\n          -  Interferon.\n\n          -  Systemic chemotherapy other than Ara-C (unless specifically allowed).\n\n          -  Antiretroviral medications other than AZT, ddI, or ddC.\n\n        Patients with the following prior conditions are excluded:\n\n        History of allergy or intolerance to G-CSF.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Any prior Ara-C.\n\n        Excluded within 14 days prior to study:\n\n          -  Ganciclovir or foscarnet.\n\n          -  Interferon.\n\n          -  Antiretroviral medications other than AZT, ddI, or ddC.\n\n          -  Experimental medications for treatment of PML."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "90", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001048", 
            "org_study_id": "ACTG 243", 
            "secondary_id": "11220"
        }, 
        "intervention": [
            {
                "intervention_name": "Filgrastim", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Cytarabine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zalcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Didanosine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Zalcitabine", 
                "Didanosine", 
                "Zidovudine", 
                "Lenograstim"
            ]
        }, 
        "keyword": [
            "Leukoencephalopathy, Progressive Multifocal", 
            "Infusions, Intravenous", 
            "Cytarabine", 
            "Zalcitabine", 
            "Didanosine", 
            "Drug Therapy, Combination", 
            "Granulocyte Colony-Stimulating Factor", 
            "Acquired Immunodeficiency Syndrome", 
            "Zidovudine", 
            "Injections, Spinal"
        ], 
        "lastchanged_date": "April 2, 2012", 
        "link": [
            {
                "description": "Click here for more information about Zidovudine", 
                "url": "http://aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=4"
            }, 
            {
                "description": "Click here for more information about Didanosine", 
                "url": "http://aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=16"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80262"
                    }, 
                    "name": "University of Colorado Hospital CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "331361013"
                    }, 
                    "name": "Univ. of Miami AIDS CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins Adult AIDS CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital ACTG CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }, 
                    "name": "Washington U CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "Univ. of Rochester ACTG CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "275997215"
                    }, 
                    "name": "Unc Aids Crs"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "981224304"
                    }, 
                    "name": "University of Washington AIDS CRS"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Multicenter Study Comparing Antiretroviral Therapy Alone to Antiretroviral Therapy Plus Cytosine Arabinoside (Cytarabine; Ara-C) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in Human Immunodeficiency Virus (HIV)-Infected Subjects", 
        "overall_official": [
            {
                "last_name": "Hall C", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Timpone J", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "reference": [
            {
                "PMID": "11364014", 
                "citation": "[No authors listed] Cytarabine nixed for PML. GMHC Treat Issues. 1996 Nov;10(11):9. No abstract available."
            }, 
            {
                "PMID": "10588116", 
                "citation": "Post MJ, Yiannoutsos C, Simpson D, Booss J, Clifford DB, Cohen B, McArthur JC, Hall CD. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. AJNR Am J Neuroradiol. 1999 Nov-Dec;20(10):1896-906."
            }, 
            {
                "citation": "Hall C, Timpone J, Dafni I, Antonijevic Z, Millar L, Booss J, Clifford D, Cohen B, McArthur J, Hollander H. ARA-C treatment of PML in AIDS patients. Conf Retroviruses Opportunistic Infect.1997 Jan 22-26;4th:66 (abstract no 8)PMID: 97926517"
            }, 
            {
                "PMID": "10360779", 
                "citation": "Yiannoutsos CT, Major EO, Curfman B, Jensen PN, Gravell M, Hou J, Clifford DB, Hall CD. Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. Ann Neurol. 1999 Jun;45(6):816-21."
            }, 
            {
                "PMID": "9571254", 
                "citation": "Hall CD, Dafni U, Simpson D, Clifford D, Wetherill PE, Cohen B, McArthur J, Hollander H, Yainnoutsos C, Major E, Millar L, Timpone J. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med. 1998 May 7;338(19):1345-51."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001048"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Bristol-Myers Squibb", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Upjohn", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2012"
    }, 
    "geocoordinates": {
        "Johns Hopkins Adult AIDS CRS": "39.29 -76.612", 
        "Massachusetts General Hospital ACTG CRS": "42.358 -71.06", 
        "Northwestern University CRS": "41.878 -87.63", 
        "Unc Aids Crs": "35.913 -79.056", 
        "Univ. of Miami AIDS CRS": "25.789 -80.226", 
        "Univ. of Rochester ACTG CRS": "43.161 -77.611", 
        "University of Colorado Hospital CRS": "39.729 -104.832", 
        "University of Washington AIDS CRS": "47.606 -122.332", 
        "Washington U CRS": "38.627 -90.199"
    }
}